Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Amgen delivered a strong fourth quarter of 2025 and looks well-positioned to absorb the LOEs on Prolia, Xgeva, and Ravicti in ...